Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Schizophrenia Research|November 24, 2022
Computerized cognitive and social cognition training in schizophrenia for impulsive aggressionAnzalee Khan, Jean-Pierre Lindenmayer, Beverly Insel, et al.
Journal of Clinical Psychopharmacology|May 15, 2002
Antipsychotic-induced weight gain and therapeutic response: a differential associationPál Czobor, Jan Volavka, Brian Sheitman, et al.
Schizophrenia Research|May 12, 2010
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month studyRobert C Smith, Jean-Pierre Lindenmayer, Qiaoyan Hu, et al.
The American Journal of Psychiatry|February 2, 2002
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorderJan Volavka, Pal Czobor, Brian Sheitman, et al.
The American Journal of Psychiatry|February 4, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychoticsJean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, et al.
The Journal of Clinical Psychiatry|October 10, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month studyRobert C Smith, Jean-Pierre Lindenmayer, John M Davis, et al.
Focus (American Psychiatric Publishing)|December 21, 2020
The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future ResearchSteven G Potkin, John M Kane, Christoph U Correll, et al.
Schizophrenia Research|July 22, 2020
Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophreniaJean-Pierre Lindenmayer, Abraham Goldring, Sophia Borne, et al.
NPJ Schizophrenia|January 9, 2020
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future researchSteven G Potkin, John M Kane, Christoph U Correll, et al.
The Journal of Clinical Psychiatry|January 7, 2015
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Pageof 10